MCID: CRN020
MIFTS: 39

Coronary Restenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Coronary Restenosis

MalaCards integrated aliases for Coronary Restenosis:

Name: Coronary Restenosis 12 54 44 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4247
MeSH 44 D023903
UMLS 70 C0948480

Summaries for Coronary Restenosis

MalaCards based summary : Coronary Restenosis is related to intermediate coronary syndrome and atherosclerosis susceptibility. An important gene associated with Coronary Restenosis is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are ECM-receptor interaction and Cellular senescence (KEGG). The drugs Thalidomide and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include endothelial, smooth muscle and heart, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Coronary Restenosis

Diseases related to Coronary Restenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 intermediate coronary syndrome 30.5 SERPINC1 PLAT ACE
2 atherosclerosis susceptibility 29.7 FABP4 CETP ACE
3 lipoprotein quantitative trait locus 29.3 TLR2 PLAT CETP CDKN2B CDKN2A ACE
4 type 2 diabetes mellitus 28.7 SPP1 SERPINC1 PLAT FABP4 CETP CDKN2B
5 myocardial infarction 28.6 TLR2 SERPINC1 PLAT CETP CDKN2B CDKN2A
6 coronary stenosis 10.4
7 lateral myocardial infarction 10.3 SERPINC1 ACE
8 cholesterol embolism 10.3 SERPINC1 ACE
9 mild cognitive impairment 10.3 ADRA2B ACE
10 anterolateral myocardial infarction 10.3 PLAT ACE
11 basilar artery insufficiency 10.3 PLAT CETP
12 inferior myocardial infarction 10.3 PLAT ACE
13 angina pectoris 10.2
14 fibrinolytic defect 10.2 SERPINC1 PLAT
15 proliferative verrucous leukoplakia 10.2 TLR2 CDKN2A
16 cranial nerve palsy 10.2 SERPINC1 ACE
17 platelet aggregation, spontaneous 10.2 SERPINC1 PLAT
18 anterior cerebral artery infarction 10.2 SERPINC1 PLAT
19 argentine hemorrhagic fever 10.2 SERPINC1 PLAT
20 central retinal artery occlusion 10.2 SERPINC1 PLAT
21 hereditary angioedema with normal c1inh 10.2 TLR2 PLAT ACE
22 coronary heart disease 1 10.1
23 heart disease 10.1
24 acute myocardial infarction 10.1
25 cardiac tamponade 10.1 PLAT ACE
26 intracranial embolism 10.1 SERPINC1 PLAT ACE
27 human papillomavirus infectious disease 10.1 CDKN2A CDKN1A
28 pulmonary artery disease 10.1 SERPINC1 PLAT ACE
29 vein disease 10.1 SERPINC1 PLAT ACE
30 suppressor of tumorigenicity 3 10.1 CDKN2A CDKN1A
31 carotid artery thrombosis 10.1 SERPINC1 PLAT
32 endocarditis 10.1 TLR2 SERPINC1 PLAT
33 pulmonary embolism 10.1 SERPINC1 PLAT ACE
34 inflammatory bowel disease 14 10.1 SPP1 FABP4
35 atrial heart septal defect 10.1 SERPINC1 PLAT ACE
36 encephalopathy, familial, with neuroserpin inclusion bodies 10.1 SERPINC1 PLAT
37 patent foramen ovale 10.1 SERPINC1 PLAT ACE
38 aortic atherosclerosis 10.1 SPP1 CETP ACE
39 arteries, anomalies of 10.0
40 adult malignant schwannoma 10.0 SPP1 CDKN2A
41 thyroid lymphoma 10.0 CDKN2B CDKN2A
42 primary cutaneous b-cell lymphoma 10.0 CDKN2B CDKN2A
43 post-thrombotic syndrome 10.0 SERPINC1 PLAT
44 chondromyxoid fibroma 10.0 CDKN2A CDKN1A
45 integumentary system disease 10.0 TLR2 CDKN2A ACE
46 melanoma-astrocytoma syndrome 10.0 CDKN2B CDKN2A
47 invasive bladder transitional cell carcinoma 10.0 IFI27 CDKN1A
48 peripheral vascular disease 10.0 SERPINC1 PLAT CETP ACE
49 tenosynovial giant cell tumor 10.0 CDKN2B CDKN2A
50 idiopathic eosinophilic pneumonia 10.0 ITGB2 ITGA4

Graphical network of the top 20 diseases related to Coronary Restenosis:



Diseases related to Coronary Restenosis

Symptoms & Phenotypes for Coronary Restenosis

MGI Mouse Phenotypes related to Coronary Restenosis:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.24 ACE ADRA2B CDKN1A CDKN2A FABP4 ITGA4
2 hematopoietic system MP:0005397 10.23 ACE ADRA2B CDKN1A CDKN2A CDKN2B ITGA4
3 cellular MP:0005384 10.22 ADRA2B CDKN1A CDKN2A CDKN2B FABP4 ITGA4
4 homeostasis/metabolism MP:0005376 10.21 ACE ADRA2B CDKN1A CDKN2A CDKN2B FABP4
5 immune system MP:0005387 10.14 ACE CDKN1A CDKN2A CDKN2B ITGA4 ITGB2
6 mortality/aging MP:0010768 10.1 ACE ADRA2B CDKN1A CDKN2A CDKN2B FABP4
7 liver/biliary system MP:0005370 9.91 ACE CDKN1A CDKN2A FABP4 SERPINC1 SPP1
8 muscle MP:0005369 9.86 ADRA2B CDKN1A CDKN2A FABP4 PLAT SERPINC1
9 neoplasm MP:0002006 9.63 ACE CDKN1A CDKN2A CDKN2B SPP1 TLR2
10 renal/urinary system MP:0005367 9.5 ACE ADRA2B CDKN1A CDKN2B SERPINC1 SPP1
11 reproductive system MP:0005389 9.23 ACE ADRA2B CDKN1A CDKN2A CDKN2B PLAT

Drugs & Therapeutics for Coronary Restenosis

Drugs for Coronary Restenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
2
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
6
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
7
Probucol Approved, Investigational Phase 4 23288-49-5 4912
8
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
13
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
14 Angiogenesis Inhibitors Phase 4
15 Cyclooxygenase 2 Inhibitors Phase 4
16 Hematinics Phase 4
17 Epoetin alfa Phase 4 113427-24-0
18 Anti-Infective Agents Phase 4
19 Anti-Bacterial Agents Phase 4
20 Antibiotics, Antitubercular Phase 4
21 Antifungal Agents Phase 4
22 Anticholesteremic Agents Phase 4
23 Antimetabolites Phase 4
24 Antioxidants Phase 4
25 Protective Agents Phase 4
26 Hypolipidemic Agents Phase 4
27 Lipid Regulating Agents Phase 4
28 Antirheumatic Agents Phase 4
29 Cyclooxygenase Inhibitors Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Analgesics Phase 4
32 Analgesics, Non-Narcotic Phase 4
33 Purinergic P2Y Receptor Antagonists Phase 4
34 Fibrinolytic Agents Phase 4
35 Neurotransmitter Agents Phase 4
36 Prasugrel hydrochloride Phase 4 389574-19-0
37 Platelet Aggregation Inhibitors Phase 4
38 Antipyretics Phase 4
39 Radiopharmaceuticals Phase 4
40 Technetium Tc 99m Sestamibi Phase 4
41 Estradiol 3-benzoate Phase 4
42 Estradiol 17 beta-cypionate Phase 4
43 Immunosuppressive Agents Phase 4
44 Immunologic Factors Phase 4
45 Tubulin Modulators Phase 4
46 Albumin-Bound Paclitaxel Phase 4
47 Antimitotic Agents Phase 4
48
Nutmeg Approved Phase 3
49
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
50 Mace Phase 3

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation - The TOP RACER Trial Unknown status NCT01638078 Phase 4 Thalidomide;Placebo
2 Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions Unknown status NCT02300454 Phase 4
3 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
4 Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) Unknown status NCT00423020 Phase 4 Erythropoietin
5 PercutAneous INTervention With Biodegradable- Polymer Based Paclitaxel-eluting, Sirolimus-eluting, or Bare Stents for the Treatment of de Novo Coronary Lesions. Completed NCT00752362 Phase 4
6 A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Impact of Oral Sirolimus on Restenosis Prevention in Patients With In-Stent Restenosis. Completed NCT00859183 Phase 4 Sirolimus;Sirolimus;Placebo
7 Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions. Completed NCT00552669 Phase 4 Oral sirolimus
8 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
9 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
10 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4
11 Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V Completed NCT00714545 Phase 4
12 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT01171820 Phase 4
13 Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis Completed NCT00598533 Phase 4
14 XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT) Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
15 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
16 Model Project for the Reduction of Coronary Restenosis Completed NCT00627900 Phase 4
17 EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease. Completed NCT00531011 Phase 4
18 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
19 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT00402272 Phase 4
20 Cardiolite-406; A Phase IV Open-Label, Randomized, Multi-Center Trial To Evaluate The Ability of Cardiolite Stress MPI to Detect Asymptomatic Restenosis in Diabetic Patients Who Have Undergone Percutaneous Coronary Intervention Completed NCT00162357 Phase 4 Technetium Tc99m Sestamibi
21 Randomized Trial of Paclitaxel- vs Sirolimus-eluting Stents for Treatment of Coronary Restenosis in Sirolimus-eluting Stents Completed NCT00598715 Phase 4
22 Prospective, Randomized Trial of Rapamycin Plus Estradiol-Eluting Stents Versus Rapamycin-Eluting Stents For The Reduction of Coronary Restenosis (ISAR-PEACE) Completed NCT00402636 Phase 4
23 Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3) Completed NCT00350454 Phase 4
24 Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis Completed NCT00332397 Phase 4
25 Treatment of Drug-Eluting Stent REstenosis Using Drug-Eluting STents vs. Drug-COated Balloon for Preventing REcurrent In-Stent Restenosis Terminated NCT01967199 Phase 4
26 Monocenter, Double Blinded, Prospective, Randomized Placebo Controlled Study Investigating Prevention of Major Adverse Cardiac Events (MACEs) Within 6 Months by Systemic Treatment With Everolimus After Coronary Intervention With Bare Metal Stents in Patients With Significant Coronary Artery Disease Unknown status NCT00426049 Phase 3 Everolimus
27 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
28 SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions Completed NCT00307047 Phase 3
29 XERES Trial: Clinical Evaluation of Patients With Everolimus-eluting Stent " Xience V® " Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period Completed NCT00882219 Phase 3
30 A Prospective, Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis Completed NCT00287573 Phase 2, Phase 3
31 SPIRIT PRIME Clinical Trial. Completed NCT00916370 Phase 3
32 A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels. Completed NCT00055510 Phase 2, Phase 3 BO-653
33 A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS™ Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions Completed NCT00148356 Phase 2, Phase 3
34 SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions Completed NCT00180479 Phase 3
35 A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions Completed NCT00180310 Phase 3
36 Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Sirolimus-Eluting and Iopromide-Coated Paclitaxel-Eluting Balloon Catheters Recruiting NCT03667313 Phase 3
37 Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated SEQUENT® SCB RAPID EXCHANGE PTCA Balloon Catheter or a Paclitaxel Coated SEQUENT® PLEASE PTCA Balloon Catheter Active, not recruiting NCT03242096 Phase 2, Phase 3
38 A Pilot Study to Evaluate the Efficacy and Safety of Different Bindarit Dosages in Preventing Stent Restenosis Completed NCT01269242 Phase 2 bindarit;bindarit;placebo
39 Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study Completed NCT01274234 Phase 1, Phase 2
40 Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons Completed NCT00106587 Phase 1, Phase 2
41 Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II) Completed NCT00409981 Phase 1, Phase 2
42 A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis Completed NCT00124943 Phase 1, Phase 2 Nanoparticle Paclitaxel
43 APPRAISAL Trial: A Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of RESTEN-MP® When Used in Conjunction With a Bare Metal Stent in de Novo Native Coronary Artery Lesions Completed NCT00248066 Phase 2 RESTEN-MP
44 A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System as Compared to the TAXUS™ Express2™ Paclitaxel-Eluting Stent in de Novo Coronary Artery Lesions Completed NCT00140101 Phase 2
45 A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina) Terminated NCT00243308 Phase 2 Serine proteinase-1 (Serp-1)
46 Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals Unknown status NCT00973375
47 BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the SiroLimus Eluting Orsiro Stent Within Daily Clinical Practice in Small Vessels Unknown status NCT03600948
48 SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI Unknown status NCT03474432
49 A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding. Unknown status NCT01623180
50 Postmarketing Surveillance Registry to Monitor Everolimus-eluting Bioresorbable Vascular Scaffold Following Rotational Atherectomy for the Treatment of Complex Coronary Lesions - The ASSURE ROT Registry Unknown status NCT01915420

Search NIH Clinical Center for Coronary Restenosis

Cochrane evidence based reviews: coronary restenosis

Genetic Tests for Coronary Restenosis

Anatomical Context for Coronary Restenosis

MalaCards organs/tissues related to Coronary Restenosis:

40
Endothelial, Smooth Muscle, Heart, Bone Marrow, Adipocyte, Liver, Thyroid

Publications for Coronary Restenosis

Articles related to Coronary Restenosis:

(show top 50) (show all 495)
# Title Authors PMID Year
1
Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. 54 61
9256478 1997
2
Predictive value of inflammatory factors on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis. 61
33787637 2021
3
Predictive value of miRNA-21 on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis. 61
33725861 2021
4
Predictive value of LncRNA on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis. 61
33429779 2021
5
BOP1 Knockdown Attenuates Neointimal Hyperplasia by Activating p53 and Inhibiting Nascent Protein Synthesis. 61
33510838 2021
6
Histopathologic response after hydrophilic polyethylene glycol-coating stent and hydrophobic octadecylthiol-coating stent implantations in porcine coronary restenosis model. 61
33247775 2020
7
High low-density lipoprotein cholesterol as an independent risk factor for coronary restenosis in hemodialysis patients undergoing percutaneous coronary interventions. 61
32643821 2020
8
The application and value of continuous nursing in patients after coronary artery bypass grafting. 61
32650829 2020
9
Relationship of left atrial expansion index to exercise tolerance, pretest probability of restenosis, and positive predictive value of treadmill test in coronary artery disease. 61
32077515 2020
10
[The Incidence and Possible Predictors of Coronary Restenosis]. 61
32345193 2020
11
Transmural variation in microvascular remodeling following percutaneous revascularization of a chronic coronary stenosis in swine. 61
32056445 2020
12
[A survey of Belgian practice for non-malignant diseases]. 61
31980359 2020
13
Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. 61
31605272 2020
14
Effects of rehabilitation exercise on coronary artery after percutaneous coronary intervention in patients with coronary heart disease: a systematic review and meta-analysis. 61
29991296 2019
15
miR-196a2 (rs11614913) polymorphism is associated with coronary artery disease, but not with in-stent coronary restenosis. 61
30560371 2019
16
[Coronary restenosis]. 61
30569181 2019
17
Coronary restenosis of in-stent protruding bump with rapid progression: Optical frequency domain imaging and angioscopic observation. 61
30693051 2019
18
One-Year Follow-Up Results From the Observational, Multicenter, Prospective, and Controlled Registry: The WALTZ All-Comers Study. 61
31285655 2019
19
Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease. 61
29716394 2018
20
Effect of various Danshen injections on patients with coronary heart disease after percutaneous coronary intervention: A protocol for a systematic review and network meta-analysis. 61
29901609 2018
21
Third generation dual-source CT enables accurate diagnosis of coronary restenosis in all size stents with low radiation dose and preserved image quality. 61
29349698 2018
22
Five-year follow-up of the endothelial progenitor cell capturing stent versus the paxlitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis. 61
28868810 2018
23
Anti-Inflammatory Effect of Gallic Acid-Eluting Stent in a Porcine Coronary Restenosis Model. 61
29844643 2018
24
Associations between endothelial progenitor cells, clinical characteristics and coronary restenosis in patients undergoing percutaneous coronary artery intervention. 61
29739448 2018
25
Novel Polymer-Free Everolimus-Eluting Stent Fabricated using Femtosecond Laser Improves Re-endothelialization and Anti-inflammation. 61
29743620 2018
26
Incidence, procedural management, and clinical outcomes of coronary in-stent restenosis: Insights from the National VA CART Program. 61
28657149 2018
27
Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. 61
29991926 2018
28
Recurrent coronary restenosis treated with Chinese medicine: A case report. 61
28861805 2017
29
Restenosis After Everolimus-eluting Vascular Scaffolding. Angiographic and Optical Coherence Tomography Characterization. 61
28132761 2017
30
Tracking delivery of a drug surrogate in the porcine heart using photoacoustic imaging and spectroscopy. 61
28192566 2017
31
Assessment of myocardial ischemia by strain dobutamine stress echocardiography and cardiac magnetic resonance perfusion imaging before and after coronary artery bypass grafting. 61
28165159 2017
32
Drug- and Gene-eluting Stents for Preventing Coronary Restenosis. 61
28184335 2017
33
The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model. 61
28154600 2017
34
Effect of Stents Coated with Artemisinin or Dihydroartemisinin in a Porcine Coronary Restenosis Model. 61
28154599 2017
35
Combination of drug-coated balloon angioplasty and excimer laser coronary angioplasty ablation for coronary restenosis of Kawasaki disease: A case report. 61
30524575 2017
36
QT Dispersion and Age; Independent Predictors of Restenosis after Percutaneous Coronary Intervention. 61
27633966 2017
37
Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). 61
27634828 2016
38
Impact of Angiographic Result After Predilatation on Outcome After Drug-Coated Balloon Treatment of In-Stent Coronary Restenosis. 61
27634028 2016
39
A novel polymer-free drug-eluting stent coated with everolimus using nitrogen-doped titanium dioxide film deposition in a porcine coronary restenosis model. 61
27505330 2016
40
Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation. 61
26337618 2016
41
Stress Testing After Complete and Successful Coronary Revascularization. 61
27038505 2016
42
Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. 61
26891035 2016
43
Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial. 61
27017366 2016
44
Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model. 61
26886814 2016
45
Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction. Long-term results of the REVIVAL-2 trial. 61
26790705 2016
46
Stent linker effect in a porcine coronary restenosis model. 61
26318568 2016
47
[Efficacy and mechanism of local delivery of rapamycin and rapamycin-loaded poly(lactic-co-glycolic) acid nanoparticles on coronary restenosis of injury-stenosis model of minipigs]. 61
26792606 2016
48
Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model. 61
27976797 2016
49
Vitamin D Supplementation Reduces Intimal Hyperplasia and Restenosis following Coronary Intervention in Atherosclerotic Swine. 61
27271180 2016
50
Association of ACE insertion or deletion polymorphisms with the risk of coronary restenosis after percutaneous coronary intervention: A meta-analysis. 61
26195267 2015

Variations for Coronary Restenosis

Expression for Coronary Restenosis

Search GEO for disease gene expression data for Coronary Restenosis.

Pathways for Coronary Restenosis

Pathways related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.85 SPP1 ITGB2 ITGA4
2 11.83 CDKN2B CDKN2A CDKN1A
3 11.71 SERPINC1 PLAT ITGB2
4
Show member pathways
11.53 CDKN2B CDKN2A CDKN1A
5 11.46 PLAT CDKN2A CDKN1A
6 11.26 TLR2 ITGB2 ITGA4
7 11.26 ITGB2 CDKN2B CDKN2A CDKN1A
8 10.95 TLR2 ITGB2 ITGA4
9 10.79 PLAT ACE
10
Show member pathways
10.75 CDKN2A CDKN1A

GO Terms for Coronary Restenosis

Cellular components related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 TLR2 PLAT ITGB2 ITGA4 ADRA2B
2 extracellular exosome GO:0070062 9.23 SPP1 SERPINC1 PLAT ITGB2 ITGA4 FABP4

Biological processes related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.61 CDKN2B CDKN2A CDKN1A
2 regulation of vasoconstriction GO:0019229 9.46 ADRA2B ACE
3 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.43 CDKN2B CDKN2A CDKN1A
4 replicative senescence GO:0090399 9.4 CDKN2A CDKN1A
5 cellular response to extracellular stimulus GO:0031668 9.37 CDKN2B CDKN1A
6 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.33 CDKN2B CDKN2A CDKN1A
7 regulation of protein export from nucleus GO:0046825 9.32 IFI27 CDKN2A
8 cellular senescence GO:0090398 9.13 CDKN2B CDKN2A CDKN1A
9 negative regulation of phosphorylation GO:0042326 8.8 CDKN2B CDKN2A CDKN1A

Molecular functions related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.13 SPP1 ITGB2 ITGA4
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CDKN2B CDKN2A CDKN1A

Sources for Coronary Restenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....